Highest-materiality recent filing
Longeveron announces 1-for-10 reverse stock split effective Aug 26, 2026
Reverse split effective 11:59 pm ET Aug 26; Class A trades split-adjusted Aug 27 on Nasdaq under LGVN, new CUSIP 54303L302.
Longeveron appoints Nirav Jhaveri as CFO; effective August 17, 2026
Nirav S. Jhaveri named CFO and principal financial/accounting officer, effective Aug 17, 2026.
Longeveron Q2 net loss widens to $6.1M; cash $10.1M into Q4 2026; ELPIS II top-line Sept
Revenue flat at $0.3M; gross profit up 25% to ~$0.2M; G&A up 23% to $3.2M; R&D up 7% to $3.2M.
Longeveron appoints new CFO, shareholders approve reverse split and authorized share increase
Marie Washburn appointed SVP & CFO effective July 13, 2026, succeeding Lisa Locklear.
CFO Lisa Locklear to step down July 10; controller Marie Washburn expected as successor
CFO Lisa Locklear resigns effective July 10, 2026; no disagreement cited.
Longeveron reports Q1 net loss of $4.7M; cash $15.8M; HLHS trial data expected August 2026
Revenue $0.4M, net loss $4.7M vs $5.0M prior year; cash $15.8M at March 31, 2026.
Longeveron FDA Type C meeting: ELPIS II trial no longer deemed pivotal; top-line data due Aug 2026
FDA stated RVEF is not an appropriate primary endpoint; no new endpoint can be agreed while trial blinded due to NIH interim analysis.
Nasdaq grants Longeveron 180-day extension to meet $1.00 bid price rule, now due Sept 21, 2026
Extension follows prior non-compliance notice from Sept 22, 2025; original cure deadline was March 23, 2026.
Longeveron raises ~$15.9M in private placement with potential additional $15M tied to HLHS milestone
Initial gross proceeds of ~$15.9M from sale of 6,013,384 common shares at $0.52 and 11,873 Series A Preferred shares convertible at $0.52.
Longeveron appoints Stephen Willard as CEO; Powell resigns; 50% salary deferral enacted
Stephen H. Willard appointed permanent CEO effective Feb 11, 2026; succeeds interim CEO Than Powell who remains in BD role.
Longeveron Q3 net loss $17.3M; cash runs late Q1 2026; BLA for HLHS delayed to 2027
Net loss increased 45% to $17.3M for nine months ended Sept 30, 2025 vs $11.9M in prior year.
Longeveron receives Nasdaq minimum bid price deficiency notice; 180-day cure until March 23, 2026
Nasdaq notified Longeveron on Sept 22, 2025 that bid price closed below $1.00 for 30 consecutive days.
Longeveron enters $10.7M ATM equity offering with H.C. Wainwright
Up to $10.7M of Class A common stock may be sold at market prices through agent Wainwright.
CEO Wa'el Hashad steps down; Than Powell interim CEO; Joshua Hare Executive Chairman
Wa'el Hashad resigned as CEO and board member effective August 27, 2025 to pursue other opportunities.
Longeveron Q2 2025 net loss $10M; HLHS trial fully enrolled, BLA filing targeted late 2026
Revenue for H1 2025 $0.7M (-31% YoY); net loss $10.0M vs $7.5M in H1 2024.
Longeveron closes $5.0M public offering (up to $17.5M with warrants) for laromestrocel development
Gross proceeds $5.0M upfront from offering of ~5.88M shares/pre-funded warrants and 14.7M short-term warrants at $0.85 combined price.
FDA approved IND for a Phase 2 pivotal registration study of laromestrocel for pediatric DCM.
Longeveron Q1 net loss $5.0M; HLHS trial 95% enrolled, BLA on track for 2026
Q1 2025 net loss $5.0M (up 23% YoY) on revenue $0.4M (down 30%); cash $14.3M, funding late into Q3 2025.
Longeveron FY2024 revenue up 237% to $2.4M; net loss narrows 25% to $16.0M
Total revenue $2.4M (FY2023: $0.7M) driven by Bahamas Registry Trial and new manufacturing contract.
Longeveron reports H1 2024 net loss down 27%; Lomecel-B gets RMAT/Fast Track for Alzheimer's
H1 2024 net loss $7.5M (down 27% YoY from $10.3M); revenue $1.0M (up 105% YoY from $0.5M).
Longeveron raises $9.0M via registered direct offering of 2.24M shares at $4.025; warrants at $3.90
Gross proceeds of approximately $9.0M from sale of 2,236,026 shares and concurrent private placement of warrants for 2,236,026 shares.
Longeveron receives FDA Fast Track designation for Lomecel-B in mild Alzheimer's
FDA Fast Track designation granted for Lomecel-B (allogeneic cell therapy) to treat mild Alzheimer’s disease.
Longeveron receives FDA RMAT designation for Lomecel-B in mild Alzheimer's disease
FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Lomecel-B for mild Alzheimer's disease.
Longeveron raises $4.4M from warrant exercise, issues new warrants to fund Lomecel-B development
Gross proceeds of $4.4M from exercise of 1,697,891 existing warrants at $2.35/share.
Longeveron board resignations, appointment of Kender, and Nasdaq compliance cure period
Jeffrey Pfeffer and Cathy Ross resigned from the Board effective May 6 and May 8, 2024, respectively.
Longeveron raises $6.2M from warrant exercise, total $11.4M; regains Nasdaq compliance
Gross proceeds of ~$6.2M from exercise of 2,399,744 existing warrants at $2.35/share; combined with prior public offering totals ~$11.4M.
Longeveron closes $5.2M public offering of common stock and warrants
Gross proceeds ~$5.2M from 2,234,043 units at $2.35/unit (share + warrant).
Longeveron receives Nasdaq minimum bid price deficiency notice
Nasdaq notified Longeveron on March 4, 2024, that Class A common stock failed to meet $1.00 minimum bid price for 30 consecutive days.
Longeveron shareholders approve reverse stock split (1:5 to 1:15) at special meeting
Reverse stock split proposal approved with 58.8M shares for, 343k against, 187k abstain; no broker non-votes.
Longeveron announces $2.36M registered direct offering and warrant private placement
Offering of 1,355,301 shares at $1.745/share; warrants to purchase 1,355,301 shares at $1.62/share with 5.5-year term.
Offering includes 2,424,243 shares of common stock at $1.65/share and pre-funded warrants for 59,243 shares.
Longeveron announces positive Phase 2a top-line results for Lomecel-B in mild Alzheimer's disease
Primary safety endpoint met; one SAE per Lomecel-B group, none on placebo, DSMB no issues.
Longeveron enters $30M rights offering at $3.00/share with R.F. Lafferty as dealer-manager
Rights offering to raise up to $30M via transferable subscription rights; subscription price $3.00 per share.
Longeveron Inc. (the “Company”) has appointed Nirav S. Jhaveri to serve as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective August 17, 2026 (the “Effective Date”).
Marie Washburn, who has been serving as Chief Financial Officer of the Company will remain with the Company in her prior role of Vice President and Corporate Controller.
who the Company anticipates will be elevated into the CFO role upon Ms. Locklear’s departure (pending final contract).
On June 1, 2026, Ms. Lisa Locklear informed management of Longeveron Inc. (the “Company”) of her decision to step down as Chief Financial Officer, to become effective July 10, 2026.
On January 27, 2025, Mr. Neil Hare provided notice of his resignation from the Board of Directors (the “Board”) of Longeveron Inc. (the “Company”) to be effective immediately.
On May 6, 2024, Jeffrey Pfeffer gave notice of his resignation from the Board of Directors (the “Board”) of Longeveron Inc. (the “Company”) and from each committee of the Board, to be effective immediately.
On May 10, 2024, the Company’s Board appointed Richard Kender, age 68, to the Board as a Class II director, effective immediately, to fill the vacancy created by the resignation of Mr. Pfeffer.
On May 8, 2024, Cathy Ross gave notice of her resignation from the Board and from each committee of the Board, to be effective immediately.
James Clavijo, who has been serving as interim CFO on a consulting basis while the Company searched for a permanent CFO, will step down from that interim position as of July 31, 2023
Dr. K. Chris Min, the Company’s prior CMO, stepped down effective June 30, 2023.
Longeveron Inc. (“Longeveron” or the “Company”) has announced the appointment of Dr. Nataliya Agafonova M.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (“CMO”), effective July 1, 2023.
Mr. Clavijo will continue in the role of interim Chief Financial Officer beyond June 9, 2023, pursuant to the terms of a Consulting Agreement entered into by and between the Company and Mr. Clavijo, effective June 10, 2023
Max materiality 0.85 · Median 0.60 · Most common event other_material